A case of anal cancer with rapidly rising CEA in longstanding perianal Crohn disease after infliximab administration

Manabu Sato, Hitoshi Ogawa, Chikashi Shibata, Koh Miura, Toshinori Ando, Fumito Saijo, Sho Haneda, Masayuki Kakyo, Makoto Kinouchi, Kohei Fukushima, Yuji Funayama, Kenichi Takahashi, Iwao Sasaki

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Infliximab is effective in the treatment of steroid-resistant Crohn disease. However, there is clinical concern about a possible correlation between an increased risk of anorectal cancer and infliximab treatment We report a case of anorectal cancer in long-standing perianal Crohn disease. A 34-year-old patient with a long-standing perianal lesion of Crohn disease underwent 3 sessions of infliximab therapy. After therapy, the concentration of plasma CEA was 36.5ng/ml and rose to 91.4ng/ml. We suspected anorectal cancer, so abdominoperineal resection was performed. The histological findings indicated mucinous adenocarcinoma. Monitoring of patients with long-standing perianal Crohn disease is considered essential for early diagnosis of anal cancer after obtaining biopsy samples from perianal lesions. Additionally, when infliximab is started for perianal Crohn disease, thorough examination for perianal lesion should be performed.

Original languageEnglish
Pages (from-to)885-892
Number of pages8
JournalJournal of Japanese Society of Gastroenterology
Volume107
Issue number6
Publication statusPublished - 2010 Jun

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'A case of anal cancer with rapidly rising CEA in longstanding perianal Crohn disease after infliximab administration'. Together they form a unique fingerprint.

Cite this